Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alcoa

GE Vernova LLC

RadNet

Semtech

TG Therapeutics

Vertex Pharmaceuticals

None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.

Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.

BioMarin Pharmaceutical

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY). But which of these two companies is the best option for those looking for undervalued stocks?

BMRN vs. INCY: Which Stock Is the Better Value Option?

Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. New product approvals, like Niktimvo, should diversify Incyte's revenue and reduce reliance on Jakafi. The EPS miss is mostly related to elevated R&D spending, which will be critical to ease investors' fears about a potential loss of revenue from Jakafi in the coming years.

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

On Tuesday, Incyte Corporation  INCY reported third-quarter revenue of $1.14 billion, up 24% year over year, beating the consensus of $1.08 billion.

Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim's Inaugural Healthcare Innovation Conference on Monday, November 11, 2024 at 2:00 pm (EST) Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 9:30 am (GMT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global.

Incyte to Present at Upcoming Investor Conferences

Incyte stock broke out Tuesday after sales of the company's two key products beat analysts' third-quarter projections.

Incyte Breaks Out To 17-Month High As Jakafi Demand Surges

Incyte Corporation (NASDAQ:INCY ) Q3 2024 Results Conference Call October 29, 2024 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Steven Stein - Chief Medical Officer Matteo Trotta - Executive Vice President, General Manager, U.S. Dermatology Barry Flannelly - General Manager, North America Conference Call Participants Michael Schmidt - Guggenheim Jessica Fye - JPMorgan Salveen Richter - Goldman Sachs Eric Schmidt - Cantor Fitzgerald Kelly Shi - Jefferies Matt Phipps - William Blair James Shin - Deutsche Bank Vikram Purohit - Morgan Stanley Derek Archila - Wells Fargo David Lebowitz - Citibank Marc Frahm - TD Cowen Brian Abrahams - RBC Capital Markets Andy Chen - Wolfe Research Jay Olson - Oppenheimer Gavin Clark-Gartner - Evercore ISI Evan Seigerman - BMO Capital Markets Tazeen Ahmad - Bank of America Srikripa Devarakonda - ­Truist Securities Ren Benjamin - JMP Securities Operator Greetings, and welcome to the Incyte Third Quarter Financial Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Incyte Corporation (INCY) Q3 2024 Earnings Call Transcript

On Tuesday, Incyte Corporation  INCY reported third-quarter revenue of $1.14 billion, up 24% year over year and beating the consensus of $1.08 billion.

Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura

Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.

INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales

The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Incyte (INCY) Q3 Earnings

Incyte beat Wall Street estimates for third-quarter revenue and raised annual sales forecast for its top-selling drug on Tuesday, as uptake among patients remained strong.

Incyte raises 2024 sales forecast for top-selling drug Jakafi

Incyte (INCY) came out with quarterly earnings of $1.07 per share, missing the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.10 per share a year ago.

Incyte (INCY) Q3 Earnings Miss Estimates

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs.

Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #SCTopEmployers--Incyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers List.

Incyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers List

INCY's third-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.

Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program.

Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program

Genmab - ADR

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or Incyte (INCY). But which of these two stocks presents investors with the better value opportunity right now?

GMAB or INCY: Which Is the Better Value Stock Right Now?

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 29, 2024. The schedule for the press release and conference call/webcast is as follows: • Q3 2024 Press Release: October 29, 2024 at 7:00 a.m. ET • Q3 2024 Conference Call: October 29, 2024 at 8:00 a.m. ET • Domestic Dial-In Number: 877-407-3042 • International Dial-In Number: 201-389-0864 • Conference.

Incyte to Report Third Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise investors to wait and watch before turning positive.

Incyte Gains 12.7% Year to Date: How Should You Play the Stock?

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Multiple Late-Breaking Data Presentations from Incyte's Dermatology Portfolio will be Featured at the EADV 2024 Congress.

Multiple Late-Breaking Data Presentations from Incyte's Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress

Syndax Pharmaceuticals

– Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg every 2 weeks dose achieving a complete or partial response within the first six months of treatment – – Niktimvo approved by U.S. FDA for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg – – Niktimvo added to latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of chronic GVHD – WILMINGTON, Del. and WALTHAM, Mass.

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease

Truist Securities has downgraded Incyte Corporation INCY, noting Jakafi's (ruxolitinib) patent loss approaching in 2028.

Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets

INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dependency.

News for Incyte Stock (INCY)